Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...

By now, we’ve all heard of the GLP-1 diabetes and weight-loss drugs from the likes of Eli Lilly (LLY) and Novo Nordisk (NVO).

A new tally finds that nearly half of the U.S. adult population might be eligible to take semaglutide to battle obesity, ...